Deep Track Capital and Frazier Life Sciences co-led the financing round, with Logos Capital and Janus ... for the treatment of chronic kidney disease and phenylketonuria, with Phase I trial ...

The focus remains on the phenylketonuria and Huntington’s disease programs, and Cantor sees more than 50% upside alone for the current risk-adjusted opportunity in PKU and HD. The firm continues ...